skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon


In Vivo(インビボ)は主に「成長」「イノベーション」「リーダーシップ」「マーケットアクセス」「マーケットインテリジェンス」の5つの観点から世界の医療用医薬品産業のトレンドを取材しています。

世界の開発パイプラインを分析したインフォーマ・ファーマインテリジェンス発行のレポート「Pharma R&D Annual Review 2018」によると、日本は創薬能力では世界第2位、市場規模でも3位につけています。欧米の新薬創出国と比較して劣っているわけではありません。


In Vivoを読むことによって、経営に携わる人々は根拠をもって意思決定をし、リスクをコントロールできるようになります。In Vivoは今日の経営層または新規ビジネス開発担当者にとっては必須のビジネスツールです。

経営戦略・トップマネジメントの視点から研究開発や財務戦略なども含む医薬品産業ニュースを読めるのはIn Vivoだけです。特集記事、注目の人物、KOLの独占インタビュー、業界幹部の異動情報なども充実しています。




  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Sun Finds US ‘Challenging’

    By Penelope MacRae 17 Feb 2020

    Sun Pharma’s Indian domestic operations posted strong sales in the third quarter, but this was not enough to prevent the company from reporting a 26% tumble in consolidated net profit in the face of a “challenging” US generics market and slow approvals for complex products.

    Topic deal-trends

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Who’s Hired? Sandoz Germany Seeks A New Country Head

    By Akriti Seth 29 Jan 2020

    While Sandoz looks for a new country head in Germany, Lupin has appointed a new chief corporate development officer and a Coherus executive has left the firm.

    Topic business-strategies

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Celltrion Sets Out Strategy For China

    By David Wallace 27 Jan 2020

    Celltrion has unveiled plans to construct a biologics plant in Wuhan, China, as well as setting up a direct sales network in the country, as part of its wider global strategy that also involves launching a new biosimilar every year to 2030.

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Coherus Is Confident After US Ranibizumab Filing

    By Aidan Fry 27 Jan 2020


    Having seen its development partner Bioeq file with the FDA in December last year, Coherus is confident that it will be a leader in the US biosimilar ranibizumab market targeting Lucentis.

    Topic Biosimilars Deal trends

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    California Plans To Create Own Generics Label

    15 Jan 2020

    California’s 2020-2021 fiscal budget includes plans to work with manufacturers to establish the state’s own generics label. But industry is sceptical that the initiative will deliver the savings that the US state hopes for.

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Biocon Biologics Gets True North Investment

    By Vibha Ravi 08 Jan 2020


    Private equity group True North continues to back the Biocon group and is picking up a minority stake in Biocon Biologics in a deal that values the subsidiary at $3bn. Separately, another subsidiary, Biocon Biosphere, has also been set up as part of efforts to unlock the full potential of the business.

    Topic deal-trends strategy

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Alberta Is Second Canadian Province To Switch To Biosimilars

    18 Dec 2019

    Alberta has become the second Canadian province to announce a biosimilar switching program, following the example set by British Columbia earlier this year. The move has been welcomed by Biosimilars Canada but criticized by originator-backed body Crohn’s and Colitis Canada.

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Global Industry Hails Bioequivalence Progress

    By Aidan Fry 11 Dec 2019

    For the first time, a working group within the International Council for Harmonization has started work on a regulatory topic specifically tailored to the global generics and biosimilars industry.

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Ophthalmics Are Next Frontier For Teligent

    06 Dec 2019

    US niche generics player Teligent intends to use its expertise in topical and injectable drugs manufacturing to push into the North American ophthalmics sector.

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Celltrion's Remsima SC Ready For Early 2020 Launch

    28 Nov 2019

    Celltrion says it is ready to roll out its Remsima SC subcutaneous infliximab in Europe in the first quarter of 2020, after receiving a formal pan-European marketing authorization from the European Commission.

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Amneal Starts Seeking International Partners

    20 Nov 2019

    In a bid to make better use of Amneal’s US portfolio and pipeline, the company is looking for international licensing partners, especially in Eastern Europe and China, as its new management team looks to restore growth and revive profit margins.

    Topic Business strategies

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Accord Strikes Thiotepa Deal With Adienne

    By Aidan Fry 20 Nov 2019

    Accord Healthcare has secured commercial rights to Adienne’s novel lyophilized formulation of thiotepa in Europe, extending its portfolio of cancer treatments.

    Topic business-strategies cancer

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Aurobindo Is Company Of The Year At GGB Awards

    13 Nov 2019


    Aurobindo has taken home the awards for Company of the Year and Acquisition of the Year at the Global Generics & Biosimilars Awards 2019, held in Frankfurt, Germany. Accord also received two awards, among a host of other recognized companies.

    Topic biosimilars

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Lupin Offloads Kyowa For $525m But Not Exiting Japan

    By Vibha Ravi 13 Nov 2019

    Lupin plans to invest in acquisitions and organic growth in the US and India after selling Japanese subsidiary Kyowa Pharma for an enterprise value of around $525m to Japan private equity group Unison Capital. But the Indian firm stresses it is not exiting Japan and will continue to look for marketing partnerships.

    Topic deal-trends strategy

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Teva Debuts US Rituximab At A 10% Discount

    08 Nov 2019

    Teva and Celltrion have launched the first biosimilar rituximab in the US, introducing Truxima at a 10% discount to Roche’s Rituxan.

    Topic biosimilars strategy



William Looney

Editor, Executive Editor, In Vivo


William Looney

William specializes in

  • Biopharma pipeline strategy
  • Biotech
  • Commercial Strategy
  • Market Access
  • Policy and Regulation

+40 year(s) experience


Cathy Kelly

Editor, Senior editor

Washington DC, USA

Cathy Kelly

Denise Peterson

Management, Editor In Chief, Pharma US

Washington DC, USA

Denise Peterson




電話:+81 (0)3 6273 4260